BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Report Library

All Reports
Datamonitor Healthcare Respiratory Disease Analysis: Chronic Obstructive Pulmonary Disease (COPD)

June 15, 2022

Dual bronchodilator combinations are being considered as the new gold standard over long-acting muscarinic antagonist (LAMA) Spiriva in the treatment of more severe COPD. 

IL-5 inhibitors have disappointed in the broader population of more severe COPD patients. However, ongoing studies are evaluating AstraZeneca’s Fasenra and GlaxoSmithKline's Nucala in individuals with high eosinophils. Topline results from Fasenra’s RESOLUTE and Nucala’s MATINEE trials are expected in the coming years, as are Phase III results from Sanofi and Regeneron’s dual IL-4 and IL-13 inhibitor Dupixent. 

This Datamonitor Healthcare report contains a Disease Analysis module.

Indications Covered: Chronic Obstructive Pulmonary Disease (COPD)
Back to the top Back to the top